These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24833046)

  • 1. Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.
    Kreutz RP; Owens J; Lu D; Nystrom P; Jin Y; Kreutz Y; Desta Z; Flockhart DA
    Platelets; 2015; 26(4):358-63. PubMed ID: 24833046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
    Lu D; Owens J; Kreutz RP
    Thromb Res; 2013 Aug; 132(2):e94-8. PubMed ID: 23920429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study.
    Franchi F; Rollini F; Cho JR; King R; Phoenix F; Bhatti M; DeGroat C; Tello-Montoliu A; Zenni MM; Guzman LA; Bass TA; Ajjan RA; Angiolillo DJ
    Thromb Haemost; 2016 Mar; 115(3):622-31. PubMed ID: 26633836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
    Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US
    Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation].
    Morel O; Viellard C; Faure A; Jesel L; Ohlmann P; Desprez D; Chauvin M; Roul G; Grunebaum L; Bareiss P
    Ann Cardiol Angeiol (Paris); 2007 Jan; 56(1):21-9. PubMed ID: 17343035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients.
    Lev EI; Bliden KP; Jeong YH; Pandya S; Kang K; Franzese C; Tantry US; Gurbel PA
    J Am Heart Assoc; 2014 Oct; 3(5):e001167. PubMed ID: 25332180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.
    Kreutz RP; Bitar A; Owens J; Desta Z; Breall JA; von der Lohe E; Sinha A; Vatta M; Nystrom P; Jin Y; Flockhart DA
    J Thromb Thrombolysis; 2014 Oct; 38(3):380-7. PubMed ID: 24510702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study.
    Gurbel PA; Bliden KP; Saucedo JF; Suarez TA; DiChiara J; Antonino MJ; Mahla E; Singla A; Herzog WR; Bassi AK; Hennebry TA; Gesheff TB; Tantry US
    J Am Coll Cardiol; 2009 Feb; 53(8):648-57. PubMed ID: 19232896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
    Rollini F; Franchi F; Cho JR; Degroat C; Bhatti M; Ferrante E; Patel R; Darlington A; Tello-Montoliu A; Desai B; Ferreiro J; Muniz-Lozano A; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    J Cardiovasc Transl Res; 2014 Feb; 7(1):53-63. PubMed ID: 24395495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
    Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
    Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study.
    Zhao X; Li Q; Tu C; Zeng Y; Ye Y
    Cardiovasc Diabetol; 2020 Oct; 19(1):171. PubMed ID: 33036613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G
    Expert Opin Pharmacother; 2015; 16(12):1739-47. PubMed ID: 26067422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
    Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y
    Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Platelets; 2015; 26(6):545-51. PubMed ID: 25167467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
    J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography Platelet Mapping.
    Collyer TC; Gray DJ; Sandhu R; Berridge J; Lyons G
    Br J Anaesth; 2009 Apr; 102(4):492-8. PubMed ID: 19286767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
    Duerschmied D; Ahrens I; Mauler M; Brandt C; Weidner S; Bode C; Moser M
    PLoS One; 2012; 7(2):e32656. PubMed ID: 22384279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.